Prior Authorization AI Vendor Evaluation Guide

Prior Authorization AI Vendor Evaluation Guide

A defensible vendor evaluation does more than compare features. It makes every finalist answer the same buyer-defined scope, workflow, evidence, exception, security, support, and exit questions. The output is a traceable decision record, not a leaderboard.

This guide is for healthcare technology research and procurement planning. It is not medical, clinical, legal, billing, coding, reimbursement, or compliance advice. Qualified owners should determine which rules apply to the buyer, payer program, product, data flow, and proposed use.

Use hard gates before comparison scoring. Scope and authority, interoperability, privacy and security, and exception recovery cannot be offset by a total score. A polished demo, familiar logo, or promising roadmap remains a vendor assertion until the buyer obtains and tests evidence for the proposed context.

Gate 1: fix the buyer, program, and use boundary

Start with one comparable use boundary. Name whether the buyer acts as a provider, payer, or both; the line of business; request types; drug or non-drug scope; service lines; locations; submission channels; languages; EHR; payer endpoints; and intended users. Record exclusions with equal precision.

Define where the product may assist and where a human retains authority. Separate requirement discovery, documentation support, submission, status handling, coverage decisions, denial review, appeal, and peer-review activity. “Human in the loop” is not a control unless the record states who reviews what, with which evidence, before which downstream action.

Evidence request:

• Buyer entity and provider, payer, or dual-role designation.
• Program, line of business, request type, service, drug status, location, channel, language, and endpoint inventory.
• Approved function, prohibited function, human authority, escalation path, and explicit exclusions.
• Applicable source, version, observed date, owner, and applicability rationale.

Stop rule: keep the candidate open when an owner cannot identify the buyer, program, transaction class, human authority, or excluded uses. A vendor-wide claim cannot substitute for a use-specific boundary.

Gate 2: reconstruct the transaction and authoritative sources

Map the full transaction rather than the vendor’s preferred screen. Follow requirement discovery, documentation assembly, submission, approval, denial, request for more information, appeal handoff, authorization expiration, and status reconciliation. Include portal or manual paths when they remain part of the operating reality.

For every input and output, record the authoritative source, the version or effective date, who may correct it, and where the correction must propagate. An API can return successfully while the wrong patient, plan, service, rule version, or request state remains attached.

Evidence request:

• Current-state and proposed-state workflow with trigger, owner, authoritative system, output, and downstream action.
• Coverage criteria source, rule version, effective date, update owner, and historical reconstruction method.
• Response-state mapping for approval, denial, more information, pending, expired, cancelled, and appealed requests.
• Correction, duplicate, retry, reconciliation, audit, and unresolved-case procedures.

Stop rule: fail the gate when the vendor cannot reconstruct the rule and source behind a historical output, or when the buyer cannot detect and reconcile conflicting states across systems.

Gate 3: require versioned interoperability evidence

Do not score a standard name or integration logo. Require the supported profile or implementation guide, version, endpoint, capability statement, authentication pattern, test environment, conformance result, known deviation, and upgrade path for each proposed payer and EHR combination.

Where applicable, evaluate Coverage Requirements Discovery, Documentation Templates and Rules, and Prior Authorization Support as separate workflow capabilities. A test-kit result can support conformance evidence, but it does not prove that local identities, documentation, business rules, exceptions, or reconciliation work correctly.

Evidence request:

• Endpoint, standard, profile, implementation guide, version, capability, authentication, and authorization details.
• Test kit, result, date, environment, payer and EHR combination, deviations, and unresolved errors.
• Missing-field, duplicate, timeout, partial-response, replay, retry, and idempotency results.
• Version notice, regression test, approval, rollback, and end-of-support plan.

Open rule: classify the gate as open/failed when evidence describes a roadmap, another version, or another payer and EHR combination. Do not infer local interoperability from a laboratory result.

Gate 4: trace every rule, model, and decision-support claim

Classify the mechanism before evaluating the claim: deterministic rules, predictive model, large language model, retrieval workflow, or human judgment. Products may combine several mechanisms, and each can have different sources, limitations, validation needs, and change controls.

Link every material claim to its rule source or model record. Capture the intended population and context, input requirements, validation setting, limitations, explanation available to users, override path, monitoring owner, and change notice. Preserve negative tests and disagreement records rather than reducing them to a favorable average.

Evidence request:

• Claim identifier, mechanism class, source attributes, rule or model version, and intended use.
• Vendor validation, relevant population and setting, exclusions, known failure modes, and limitation statement.
• Buyer test scenario, expected and observed result, reviewer, disagreement, override, and downstream effect.
• Monitoring threshold, change notice, regression test, approval reset, and retirement process.

Stop rule: a marketing claim, undisclosed logic, or “human oversight” statement cannot pass this gate. HTI-1 evidence is requested only after the buyer establishes that the certified-health-IT module and function are in scope.

Gate 5: pass privacy, security, resilience, and data-rights gates

Trace PHI and ePHI from creation through transmission, processing, logging, support access, retention, export, deletion, backup, and termination. Name systems, regions, subprocessors, permitted uses, access roles, and minimum-necessary rationale. Privacy, legal, and security owners—not vendor marketing—determine whether a business associate relationship and BAA are applicable.

Pair documentary review with operational scenarios. Test unavailable dependencies, lost connectivity, delayed responses, corrupted or duplicated events, security incidents, data export, termination assistance, and post-recovery reconciliation. Record who can pause processing, preserve evidence, notify affected owners, restore service, and verify downstream state.

Evidence request:

• Data-flow diagram, data inventory, permitted-use record, retention and deletion schedule, location, and subprocessor chain.
• BA and BAA applicability decision, contract evidence, access control, audit logging, risk analysis, and remediation register.
• Incident notification, downtime mode, recovery objectives, backup, restoration, reconciliation, and communication procedure.
• Data export format, portability test, deletion evidence, transition support, and termination obligation.

Stop rule: a material privacy, security, resilience, or data-rights gap cannot be offset by functionality, speed, price, or a total score. A BAA or security report is an input, not proof that the specific deployment is compliant or secure.

Gate 6: compare operations, support, commercial terms, and exit

Only vendors that have passed, or have an explicitly acceptable conditional path through, the hard gates should enter a scored comparison. Use the same volume, payer mix, request types, integrations, exception load, implementation boundary, support coverage, and contract period for every finalist.

Compare implementation work, training, staffing, support channels, escalation, service levels, change control, renewal, price dependencies, unpriced obligations, data export, transition assistance, and termination. Keep pricing inputs separate from ROI claims; neither a low price nor a positive business case resolves an evidence gap.

Evidence request:

• Common assumptions for volume, users, payer and EHR combinations, exception rate, support hours, and contract period.
• Implementation, configuration, interface, training, support, upgrade, renewal, usage, and exit inputs.
• Service levels, exclusions, escalation, change-control commitments, credits, and unresolved dependencies.
• Decision meeting, approvers, conditional actions, evidence due dates, expiry date, and re-review trigger.

Stop rule: do not rank a candidate that failed a hard gate. Keep missing or non-comparable commercial inputs open and preserve the decision rationale instead of manufacturing a complete total cost or automatic winner.

Questions by accountable owner

Prior authorization operations and utilization management

• Which payers, lines of business, request types, services, and exceptions are in scope, and which are explicitly excluded?
• Who owns final authority for approval, denial, more information, appeal, expiration, and status reconciliation?
• How will the team reconstruct the rule source, version, effective date, and historical output for a disputed case?

Integration, EHR, and payer-interface owners

• Which profile, implementation guide, and version does each endpoint actually support, and which payer and EHR combination produced the evidence?
• How are missing fields, duplicate submissions, timeouts, partial responses, retries, and idempotency detected and reconciled?
• When a standard or payer interface changes, who receives notice, runs regression tests, approves release, and can roll back?

Privacy, security, legal, and compliance owners

• Which entity relationships and data uses trigger BA, BAA, or other duties, and how are permitted uses and subprocessors recorded?
• Where is PHI or ePHI created, transmitted, retained, accessed, exported, and deleted, and how is each action audited?
• Which regulatory, HTI, device, or security claims actually apply, and which remain marketing language or a proposed rule?

Clinical, revenue-cycle, finance, and procurement owners

• Which claims have verified source, vendor documented, locally tested, or open/failed evidence, and are negative findings preserved?
• After hard gates pass, are implementation, support, renewal, exit, and unpriced obligations comparable under the same assumptions?
• Who may record pass, fail, conditional, or open, when do conditions expire, and which changes trigger re-evaluation?

Six buyer-owned artifacts

These records belong to the buyer. Each artifact should retain an evidence link, document or version, observed date, vendor owner, buyer verifier, limitation, and next action. A vendor assertion does not become verified because it appears in a proposal, and a locally tested result does not automatically transfer to another payer, service, population, configuration, or version.

A. Scope and applicability matrix

• Buyer entity and provider, payer, or dual role.
• Program, line of business, request type, drug status, service, location, channel, language, and endpoint.
• Applicable or not-applicable source, version, date, rationale, owner, and exclusion.
• Human authority, prohibited function, approval boundary, and re-review trigger.

B. Workflow and authority map

• Trigger, requirement source, documentation input, submission route, and response state.
• Approval, denial, more-information, appeal, peer-review, expiration, and cancellation ownership.
• Authoritative system, correction path, audit event, reconciliation rule, and unresolved queue.
• Human decision, pause path, override evidence, escalation, and downstream action.

C. Interface and conformance evidence pack

• Endpoint, profile, implementation guide, version, capability statement, authentication, and authorization.
• Test environment, kit, result, date, payer and EHR combination, and known deviation.
• Error, timeout, retry, duplicate, replay, partial response, idempotency, and reconciliation result.
• Upgrade notice, regression plan, approval, rollback, support period, and retirement path.

D. Claim, rule, and model evidence ledger

• Claim identifier, mechanism class, source, version, population, context, and intended use.
• Vendor document, validation setting, limitations, exclusions, and known failure modes.
• Local scenario, expected and observed result, negative result, reviewer, and disagreement.
• Explanation, override, monitoring threshold, change notice, owner, and approval reset.

E. Exception, security, and resilience test register

• Scenario, input, expected behavior, observed behavior, detectability, owner, and status.
• Wrong-patient, wrong-plan, missing data, duplicate, denial, more-information, and appeal cases.
• PHI flow, access, incident, downtime, restoration, rollback, and reconciliation evidence.
• Export, portability, deletion, termination, residual risk, remediation, and retest date.

F. Commercial comparison and decision record

• Comparable volume, user, payer, interface, exception, support, and contract assumptions.
• Implementation, training, staffing, service, renewal, usage, transition, and exit inputs.
• Unpriced item, dependency, hard-gate status, dimension rating, and unresolved evidence.
• Decision, conditional action, owner, deadline, approver, expiry, and review trigger.

Evidence states and decision rules

Use four evidence states without collapsing them into one percentage:

• verified source: the buyer can identify the authoritative record, version, observed date, applicability, and limitation.
• vendor documented: the vendor supplied a written assertion or artifact, but the buyer has not independently verified the claim in the proposed context.
• locally tested: the buyer observed the result in a named scenario, configuration, version, payer, EHR, and date; transfer beyond that boundary remains unproven.
• open/failed: required evidence is missing, contradictory, non-applicable, stale, or the observed result did not meet the acceptance condition.

Record the decision separately as pass, fail, conditional, or open. Conditional requires the action, owner, due date, required evidence, expiry, and consequence of missing the condition. An expired condition returns to open rather than silently becoming approval.

Apply hard gates before comparison scoring. Scope and applicability, decision authority, interoperability, privacy and security, and exception and recovery failures cannot be traded for features, time savings, or price. No default weight or automatic winner is supplied here.

If qualified finalists are scored, the buyer must define and version the dimensions and weights before seeing vendor results. Use only comparable assumptions, show failed and open evidence beside the dimension result, and preserve the underlying records. A total score supports discussion; it does not authorize procurement, clinical use, production use, or expansion.

Current, proposed, and conditional boundaries

The CMS Interoperability and Prior Authorization Final Rule fact sheet identifies impacted payers and separates operational provisions from later API requirements. Its Prior Authorization API scope does not cover prior authorization for drugs. It does not turn every payer, request, vendor, or deployment into the same legal or technical case, and it does not prove vendor performance.

The CMS Prior Authorization API FAQ describes response states and also notes ongoing proposals. CMS-0062-P remains proposed; it must not be treated as a final requirement. Maintain a version watch with source URL, publication status, observed date, owner, and a trigger to re-evaluate the matrix.

The CMS standards and implementation-guide page lists relevant FHIR, US Core, SMART, CRD, DTR, and PAS versions and status information. It supports versioned evidence requests, not a permanent promise that one version applies everywhere or that conformance proves local workflow correctness.

The CMS electronic prior authorization overview recommends evaluating roadmap, integration, testing, training, support, and payer participation. That guidance is not a product certification. A buyer still needs local workflow, exception, downtime, and reconciliation evidence.

The CMS prior authorization metrics reporting overview and template explains aggregate reporting for medical items and services, not drugs, and shows how measures can identify denominators, time units, and data-quality limitations. Those aggregate figures are not a local baseline or causal evidence of vendor impact.

The 2024 Medicare Advantage and Part D final rule fact sheet may inform a Medicare Advantage-specific review. Do not generalize its continuity, criteria, or utilization-management provisions to every payer or request; a qualified owner must determine applicability.

The HHS business associate guidance explains business associate relationships, BAA provisions, safeguards, incident reporting, and subcontractors. A business associate determination depends on the entities, activities, and data use. A BAA is not automatically required for every provider-payer exchange, and it does not complete deployment review.

The HHS risk analysis guidance frames risk analysis as foundational to appropriate ePHI safeguards. It does not certify a vendor or prescribe one universal assessment method; the buyer must record its environment, risks, controls, gaps, and remediation.

The NIST AI RMF Core offers voluntary Govern, Map, Measure, and Manage functions for documenting AI risk across the lifecycle. The NIST Cybersecurity Framework 2.0 release provides voluntary risk-management outcomes, including governance and supply-chain considerations. Neither framework is a healthcare approval or compliance certificate.

The HTI-1 final rule page can inform algorithm-transparency questions when a certified health IT module enables or interfaces with predictive decision support in scope. HTI-1 does not apply to every prior authorization AI product, model, or vendor; record the certification, module, function, and applicability decision first.

The 2026 CMS proposed rule fact sheet for drug prior authorization standards is evidence that drug scope and technical policy may change. It remains a proposal, not a current final requirement or guaranteed date. Track it through the version watch without importing proposed obligations into current scoring.

FAQs

Should the vendor with the highest weighted score win?

No. A failed or materially open hard gate can disqualify a candidate regardless of total score. Among qualified finalists, a versioned score can summarize comparable evidence, but the decision record must retain limitations, unresolved items, conditions, approvers, and expiry.

Does a successful API test prove the workflow is correct?

No. It may show that a particular message exchanged in a particular environment. It does not prove correct patient, plan, service, criteria, documentation, authority, exception handling, downstream state, or recovery. Test the full transaction and reconcile every system of record.

Does a BAA complete privacy and security review?

No. First determine whether the relationship and activities create business associate duties. Then evaluate permitted uses, data flow, access, safeguards, subprocessors, incidents, risk analysis, resilience, export, deletion, and termination for the proposed deployment.

Do CMS aggregate metrics prove vendor impact?

No. Preserve the payer, program, period, numerator, denominator, unit, exclusions, and data-quality limitations. Keep external aggregate reporting separate from the buyer’s reproducible local baseline and from any claim that a vendor caused a change.

Does HTI-1 apply to every prior authorization AI product?

No. Applicability depends on the certified health IT module, the function, and how predictive decision support is enabled or interfaced. Record the conclusion and qualified owner rather than turning a conditional rule into a universal checklist item.

Can a demo or roadmap count as verified evidence?

No. Record it as vendor documented until an authoritative source or bounded local test supports the claim. A demo can help select scenarios, and a roadmap can identify a dependency, but neither should be promoted to verified source or locally tested evidence.

Handoff to adjacent decision pages

Use the prior authorization tool shortlist for candidate discovery. A shortlist narrows the market; it does not approve a finalist.

Use the prior authorization buyer checklist for procurement completeness. This page owns same-scope cross-vendor comparison and does not replace the broader checklist.

Use the prior authorization workflow implementation guide for the configured workflow, cutover, downtime, rollback, reconciliation, monitoring, and release controls after a selection decision.

Use the prior authorization security review for security deep review. Privacy and security remain hard gates here, while the adjacent page owns the detailed evidence process.

Use the prior authorization pricing questions for comparable commercial inputs and the prior authorization ROI model for economic evaluation. This guide records inputs and gaps; it does not invent cost or return.

Use the prior authorization pilot planning guide for local pilot execution, baseline, cohort, scenarios, stop conditions, and expand-or-hold decisions. A vendor evaluation defines claims and exceptions to test but does not claim pilot results.

These handoffs make responsibilities visible. The vendor evaluation links to adjacent records but does not complete their reviews or authorize production use.

Evidence boundary

The official sources above support the stated policy, standards, privacy, security, and risk-management boundaries. They do not endorse a vendor, establish local applicability, prove interoperability, or demonstrate product outcomes. No vendor product test, customer interview, local deployment measurement, legal conclusion, clinical review, or completed procurement decision is claimed here.

The six gates and six artifacts are HealthAIdir’s editorial structure for organizing buyer evidence. They are not a CMS, HHS, ASTP, or NIST form; not a compliance certificate; and not a vendor ranking. Buyers should retain original records, current versions, qualified-owner conclusions, negative evidence, and unresolved limitations.

Continue your HealthAIdir research

• Define the broader category in AI for prior authorization and AI for revenue cycle.
• Record general supplier readiness in the Healthcare AI Vendor Readiness Checker.
• Structure privacy evidence with the HIPAA / BAA Evidence Checklist.
• Review prior authorization, payer-provider workflow, audit log, and denial management.
• Keep product discovery separate in reviews and side-by-side comparison work in compare pages.